Ainos, Inc. (NASDAQ:AIMD) Sees Significant Decrease in Short Interest

Ainos, Inc. (NASDAQ:AIMD) was the target of a large decline in short interest in February. As of February 27th, there was short interest totaling 83,517 shares, a decline of 15.8% from the February 12th total of 99,130 shares. Based on an average daily volume of 51,598 shares, the days-to-cover ratio is presently 1.6 days. Approximately 1.9% of the company’s stock are sold short. Approximately 1.9% of the company’s stock are sold short. Based on an average daily volume of 51,598 shares, the days-to-cover ratio is presently 1.6 days.

Insider Buying and Selling at Ainos

In other news, major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the company’s stock in a transaction that occurred on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total value of $99,820.00. Following the completion of the sale, the insider owned 989,925 shares of the company’s stock, valued at approximately $2,148,137.25. This represents a 4.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last three months, insiders have sold 47,281 shares of company stock valued at $102,152. 9.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Mariner LLC purchased a new stake in Ainos during the fourth quarter valued at approximately $37,000. Two Sigma Investments LP purchased a new position in Ainos in the third quarter worth $80,000. DRW Securities LLC grew its holdings in Ainos by 272.6% in the fourth quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after purchasing an additional 48,439 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Ainos by 13.1% during the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock worth $109,000 after purchasing an additional 7,700 shares in the last quarter.

Ainos Price Performance

AIMD opened at $1.43 on Tuesday. The business’s 50-day moving average is $1.72 and its two-hundred day moving average is $2.52. Ainos has a 1 year low of $1.26 and a 1 year high of $4.50. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.96 and a quick ratio of 2.67. The firm has a market capitalization of $6.88 million, a PE ratio of -0.36 and a beta of 2.39.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Ainos in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, Ainos presently has an average rating of “Sell”.

About Ainos

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.